Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence
Biodesix, Inc. (Nasdaq: BDSX), a prominent player in personalized diagnostics, has recently been acknowledged as a Center of Excellence (COE) by Thermo Fisher Scientific. This prestigious designation is part of Thermo Fisher’s initiative aimed at enhancing next-generation sequencing (NGS) diagnostics. The services Biodesix provides exemplify their Development Services that offer customizable diagnostics solutions to leading life sciences companies, biopharmaceutical developers, and medical research organizations.
Collaborative Efforts with Thermo Fisher
In a significant development earlier this year, Biodesix played a crucial role in the validation of the Oncomine Dx Express Test, which ultimately led to the FDA's approval of the Genexus Dx Integrated Sequencer. The validation studies conducted by Biodesix utilized rigorously controlled laboratory processes and quality management systems that are integral to their operational framework. This collaboration highlights the importance of their contributions to regulatory submissions, ensuring high-quality standards in predictive oncology.
CEO Statement
Scott Hutton, the CEO of Biodesix, expressed excitement about the partnership, stating, “Our collaboration with Thermo Fisher empowers us to continue our commitment to advancing cancer diagnostics. Joining the ranks of Thermo Fisher’s COE network enables us to work alongside other innovative global leaders dedicated to improving cancer diagnosis and treatment. We are thrilled about the prospects of offering the Oncomine Dx Express Test soon.”
Upcoming Events and Presentations
As part of their ongoing dedication to precision medicine, Biodesix will be presenting opportunities for healthcare professionals to learn about the groundbreaking NGS oncology solutions from Thermo Fisher. These presentations aim to provide insights into how Biodesix intends to leverage innovative scientific advancements for their clients across the healthcare spectrum.
Mentioned Webinars
- August 27, 2025: A Thermo Fisher Scientific Webinar will introduce the new FDA-approved rapid NGS solution for companion diagnostics and tumor profiling. It will feature notable speakers including David Chi, PhD, and Gary Pestano, PhD, Chief Development Officer at Biodesix.
- September 15, 2025: At the College of American Pathologists (CAP) 2025 Annual Meeting, there will be a Thermo Fisher-sponsored panel discussing the latest IVD solution for rapid NGS profiling in oncology. Esteemed speakers, including Mahmoud Elsayad, MD, and Alison Roos from Thermo Fisher, are set to highlight the collaborative innovations.
About Biodesix: Pioneering Diagnostic Solutions
Biodesix is at the forefront of diagnostic solutions designed to improve clinical care and outcomes for patients suffering from lung diseases. Their recognized Biodesix Diagnostic Tests, including the Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, play a critical role in supporting clinical decisions, enabling tailored care plans that enhance patient outcomes.
Development Services Offered
The company’s Development Services empower leading biopharmaceutical and research institutions with advanced scientific, technological, and operational competencies necessary for developing cutting-edge diagnostic tests and therapeutic solutions. This broad spectrum of expertise ensures that Biodesix remains a trusted partner in the medical research community.
About the Thermo Fisher COE Network
Thermo Fisher’s Center of Excellence Network collaborates with global institutions on developing and refining its Ion Torrent Oncomine solutions. This partnership fosters strategic alliances aimed at propelling oncology research and enhancing precision medicine capabilities worldwide.
Biodesix Contacts
Media Inquiries:
Natalie St. Denis, Director of Corporate Communications, Biodesix
natalie.stdenis@biodesix.com
(720) 925-9285
Investor Relations:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843
Frequently Asked Questions
What is the significance of Biodesix being a Center of Excellence?
This recognition highlights Biodesix's leadership, innovation, and commitment to advancing NGS-based diagnostics within the precision medicine field.
How does Biodesix contribute to cancer diagnostics?
Biodesix develops and validates diagnostic tests that aid in the personalized treatment of cancer patients, utilizing advanced technologies and collaborative efforts with industry leaders.
What are the upcoming events for Biodesix?
Biodesix will participate in webinars and panels discussing advancements in rapid NGS solutions and IVD technologies for oncology.
Who are the key speakers at the Thermo Fisher webinars?
Notable speakers include David Chi, PhD, Gary Pestano, PhD, and Mahmoud Elsayad, MD, among others.
How can I get in touch with Biodesix for more information?
You can reach out to Natalie St. Denis for media inquiries or Chris Brinzey for investor relations via the email addresses provided in the contact section.
